

7-29-05

PATENT

Application S/N 10/741,929

Docket No. 202.2D6

Date: July 27, 2005

MAIL STOP AMENDMENT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

TRANSMITTAL

Sir:

Transmitted herewith for filing is an information disclosure statement by Applicants.

For: **PHARMACEUTICAL COMPOSITIONS AND TREATMENT METHODS - 6**

Enclosed are:

- (X) Supplemental information disclosure 25 references.
- (X) Copies of 25 references (non-U.S. patent or patent publication) cited in the IDS.
- (X) Certificate of mailing by express mail (label No. EV 205131207 US).
- (X) Return postage prepaid postcard.

The Commissioner is hereby authorized to charge any fees which may be required, now or in the future, or credit any overpayment to **Deposit Account No. 501536**. Small entity status has previously been claimed for this application.

Please use **Customer No. 26,551** for the correspondence address.

Date: July 27, 2005

Daryl D Muenchau

Daryl D. Muenchau
Registration No. 36,616
Attorney of Record
Hollis-Eden Pharmaceuticals, Inc.
4435 Eastgate Mall, Suite 400
San Diego, CA 92121
Phone: 858-587-9333



Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


CERTIFICATE OF MAILING BY EXPRESS MAIL

Attorney Docket No. : 202.2D6
Applicant(s) : Clarence N. Ahlem, et al.
Application Serial No. : 10/741,929
For : **Pharmaceutical Compositions and
Treatment Methods - 6**
Attorney : **Daryl D. Muenchau
Registration No. 36,616**
Express Mail Label No. : EV 205131207 US
Date of Deposit : July 27, 2005

I hereby certify that the accompanying:

transmittal form, supplemental information disclosure statement for Serial No.
10/741,929 listing 25 references, copies of 25 references cited in the IDS, return
postage prepaid postcard and amendment and response to restriction requirement

are being deposited with the United States Postal Service "Express Mail Post Office to
Addressee" service under 37 C.F.R. § 1.10 on July 27, 2005 and are addressed to Mail Stop
Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Brenda Mannon

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
202.2D6APPLICATION NO.
10/741,929SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Clarence N. Ahlem, et alFILING DATE
December 19, 2003GROUP
1617

(USE SEVERAL SHEETS IF NECESSARY)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

U.S. PATENT APPLICATION PUBLICATIONS

EXAMINER INITIAL	DOCUMENT PUBLICATION NUMBER	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	H6-279488	10-04-94	Japan			X	

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	Bruder, S. P., et al., Mesenchymal stem cells in bone development, bone repair, and skeletal regeneration therapy, <i>J Cell Biochem</i> , 56(3), pp. 283-94, 1994
	Chen, Z. et al., Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. <i>J. Clin. Invest.</i> 103, pp. 401-406, 1999
	Fink, B. E. et al., Novel structural templates for estrogen-receptor ligands and Prospects for Combinatorial Synthesis of Estrogens. <i>Chem. Biol.</i> , 6, pp. 205-219, 1999
	Gao, H. et al., Comparative QSAR analysis of estrogen receptor ligands, <i>Chem. Rev.</i> , 99, pp. 723-744, 1999
	Grundy, J., Artificial Estrogens. The Technical College, Acton, London, W.S., England, pp.281-416, May 1956
	Jilka RL, et al., Increased osteoclast development after estrogen loss: mediation by interleukin-6, <i>Science</i> 257, pp. 88-91, 1992

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 202.2D6	APPLICATION NO. 10/741,929
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Clarence N. Ahlem, et al	
		FILING DATE December 19, 2003	GROUP 1617

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	Jilka, R.L. et al., Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone, <i>Journal of Clinical Investigation</i> , 104(4), pp 439-446 August 1999.
	Khosla, S. et al., Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: A key role for bioavailable estrogen. <i>J. Clin. Endocrinol. Metab.</i> 83, pp. 2266-2274, 1998
	Lea, C.K. et al., Androstenedione treatment reduces loss of cancellous bone volume in ovariectomized rats in a dose-responsive manner and the effect is not mediated by estrogen, <i>J. Endocrinol.</i> , 156, pp. 331-339, 1988
*	Ojasoo, T. and Raynaud, J. P. Unique steroid congeners and receptors studies, <i>Cancer Res.</i> , 38, pp. 4186-4198, 1978
	Oursler M. J., Estrogen regulation of gene expression in osteoblasts and osteoclasts <i>Critical Review in Eucaryotic Gene Expression</i> , 8:125-140 1998
	Picherit, C. et al., Dihydrotestosterone prevents glucocorticoid-negative effects on fetal rat metatarsal bone <i>in vitro</i> , <i>Biol. Neonate</i> , 77:181-190 2000
	Pietras, R.J. and C.M.Szego. Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells. <i>Nature</i> , 265, pp.69-72, 1977
	Plotkin, L.I., et al., Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin, <i>J. Clin. Invest.</i> 104(10):1363-1374 November 1999.
	Pomper, M. G., et al., 11 β -Methoxy-, 11 β -ethyl- and 17 α -ethynyl-substituted 16 α -fluoroestradiols: Receptor-based imaging agents with enhanced uptake efficiency and selectivity. <i>J. Med. Chem.</i> , 33, pp. 3143-3155, 1990
	Riggs, B., et al. Short- and long-term effects of estrogen and synthetic anabolic hormone in postmenopausal osteoporosis, <i>J. Clin. Invest.</i> , 51, pp.1659-1663, 1972
*	Santoro, N.F., et al. Therapeutic controversy: Hormone replacement therapy-where are we going? <i>J. Clin. Endocrinol. Metab.</i> 84, pp.1798-1812, 1999
	Scheven B.A., et al, Dehydroepiandrosterone (DHEA) and DHEA-S interact with 1,25-dihydroxyvitamin D ₃ (1,25(OH) ₂ D ₃) to stimulate human osteoblastic cell differentiation <i>Life Sciences</i> , 62, pp. 59-68, 1988
	Solmsen, U. V., Synthetic estrogens and the relation between their structure and their activity. <i>Chem. Res.</i> , 37, pp. 481-598, 1945
	Tedesco, R., Katzenellenbogen, J. A. and Napolitano, E. 7 α ,11 β -Disubstituted estrogens: Probes for the shape of the ligand binding pocket in the estrogen receptor. <i>Bioorg. Med. Chem. Lett.</i> , 7, 2919-2924 1997
	Tobias, J.H., et al., 5 α -dihydrotestosterone partially restores cancellous bone volume in osteopenic ovariectomized rats, <i>Am. J. Physiol. Endocrinol. Metab.</i> 267, pp. E853-E859, 1994.
	Watts, N. B., Clinical utility of biochemical markers of bone remodeling, <i>Clin. Chem.</i> , 45, pp. 1359-1368, 1999
	Weinstein R.S. et al., Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids <i>J. Clin. Invest.</i> 102, pp. 274-282, 1998
	Weinstein RS et al., The effects of androgen deficiency on murine bone remodeling and bone mineral density are mediated via cells of the osteoblastic lineage, <i>Endocrinology</i> 138, pp. 4013-4021, 1997

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	